Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

20/20 GeneSystems Awarded $750,000 NCI Contract

Published: Wednesday, February 26, 2014
Last Updated: Wednesday, February 26, 2014
Bookmark and Share
Award will see 20/20 develop companion diagnostic for targeted therapies in kidney cancer.

20/20 GeneSystems, Inc. announces that the NCI has awarded the company a cost-sharing Phase II Small Business Innovation and Research (SBIR) contract to develop, optimize, and validate (analytically and clinically) a test to help predict whether a patient with advanced stage kidney cancer (renal cell carcinoma) is likely to benefit from anti-angiogenic therapy. The anticipated end result is a diagnostic test that will indicate to oncologists the appropriate treatment for patients. 

With an estimated 65,000 new cases in the US in 2013 kidney cancer represents 3% of all cancers yet the disease is the 6th leading cancer death, with an estimated 13,600 deaths in 2013. Kidney cancer does not exhibit any symptoms at an early stage it therefore often remains undetected until it is advanced. Advanced renal cell carcinoma does not respond to chemotherapy and radiation. Three types of treatments are currently used: immunotherapy, anti-angiogenic agents, and mTOR inhibitors and no treatment is effective in more than a fraction of patients. Kidney cancer can progress very rapidly. Once the cancer is detected it is important to select the right treatment as quickly as possible. 

“There is a large unmet clinical need for an assay to identify kidney cancer patients likely to respond or not respond to a particular therapy. The early results which 20/20 presented last year are very promising. The 20/20 test would help guide treatment decisions and strategies so we can provide the best informed care to our patients,” says Sandy Srinivas, MD, Associate Professor of Oncology at the Stanford University School of Medicine. “There is a definite need for a companion diagnostic to predict response to anti-angiogenic drugs as there are other targeted therapies, with other mechanisms of action, which may be more suitable”. 

The development of the proof of concept development was funded by Phase I SBIR contract HHSN261201000135C from the National Cancer Institute and private funds. 

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

20/20 GeneSystems Acquires Rights to Lung Cancer Screening Test
The Company intends to develop a diagnostic that would help identify lung cancer.
Tuesday, December 20, 2005
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Biologists Induce Flatworms to Grow Heads and Brains of Other Species
Findings shed light on role of a new kind of epigenetic signaling in evolution, could yield clues for understanding birth defects and regeneration.
Fat Cells Originating from Bone Marrow Found in Humans
Cells could contribute to diabetes, heart disease.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos